{"nctId":"NCT00447772","briefTitle":"Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia","startDateStruct":{"date":"2004-10"},"conditions":["Cervical Dystonia"],"count":516,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]}],"interventions":[{"name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* De novo patients with cervical dystonia\n* Outpatient\n* Patients to be of age 18 years or older\n* Written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Pre-treatment of cervical dystonia with botulinum toxin\n* Pre-treatment with botulinum toxin for any indication other than cervical dystonia within the past 12 months\n* Pure retro- or antecollis\n* Neurological or other diseases which may affect head and neck motor function or neuromuscular transmission, e.g. polyneuropathy with pareses, myasthenia, myopathy, motor neurone diseases, Bekhterev's disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12)","description":"The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:\n\n* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)\n* Subscore B: duration of movement (values 1 or 2)\n* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)\n* Subscore D: severity and duration of tremor (range: 0-4 points).\n\nThe total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.\n\nThe mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the first on-treatment visit (Week 4 or Week 12 visit) is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"3.3"},{"groupId":"OG001","value":"-4.0","spread":"2.6"},{"groupId":"OG002","value":"-3.8","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) Between Visit 1 (Week 0) and Visit 3 (Week 12)","description":"The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:\n\n* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)\n* Subscore B: duration of movement (values 1 or 2)\n* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)\n* Subscore D: severity and duration of tremor (range: 0-4 points).\n\nThe total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.\n\nThe mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 12 visit is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.4"},{"groupId":"OG001","value":"-2.4","spread":"2.5"},{"groupId":"OG002","value":"-2.3","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Change in the Total Score of the Tsui Rating Scale (Patient Walking) Between Baseline (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)","description":"The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:\n\n* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)\n* Subscore B: duration of movement (values 1 or 2)\n* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)\n* Subscore D: severity and duration of tremor (range: 0-4 points).\n\nThe total score was calculated as follows: total score = subscores (A x B) + C + D.\n\nThe total score ranges between 0 and 25 points. A high total score represents severe CD.\n\nThe mean changes in the total score of the Tsui rating scale (patient walking) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"3.2"},{"groupId":"OG001","value":"-4.3","spread":"2.9"},{"groupId":"OG002","value":"-3.9","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.6"},{"groupId":"OG001","value":"-2.3","spread":"3.1"},{"groupId":"OG002","value":"-2.3","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Change in the 4 Subscores of the Tsui Rating Scale (Patient in the Sitting Position) Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)","description":"The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:\n\n* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)\n* Subscore B: duration of movement (values 1 or 2)\n* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)\n* Subscore D: severity and duration of tremor (range: 0-4 points).\n\nA higher score for each subscale represents severe CD symptoms. The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.\n\nThe mean changes in the subscores A to D of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.3"},{"groupId":"OG001","value":"-1.5","spread":"1.2"},{"groupId":"OG002","value":"-1.4","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.6"},{"groupId":"OG001","value":"-0.3","spread":"0.5"},{"groupId":"OG002","value":"-0.3","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.8"},{"groupId":"OG001","value":"-0.6","spread":"0.8"},{"groupId":"OG002","value":"-0.4","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.0"},{"groupId":"OG001","value":"-0.5","spread":"1.0"},{"groupId":"OG002","value":"-0.6","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.3"},{"groupId":"OG001","value":"-0.9","spread":"1.2"},{"groupId":"OG002","value":"-0.8","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.5"},{"groupId":"OG001","value":"-0.1","spread":"0.4"},{"groupId":"OG002","value":"-0.2","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.8"},{"groupId":"OG001","value":"-0.3","spread":"0.7"},{"groupId":"OG002","value":"-0.2","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.9"},{"groupId":"OG001","value":"-0.3","spread":"0.9"},{"groupId":"OG002","value":"-0.4","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change in the Craniocervical Dystonia Questionnaire (CDQ-24) Total Score and Subscores Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)","description":"The CDQ-24 is a disease-specific quality of life (QoL) instrument and was assessed at Visits 1 to 3. It consists of 24 items investigating problems in daily living skills related to CD.\n\nThis instrument is based on 5 subscales: Stigma, Emotional well-being, Pain, Activities of daily living (ADL), Social/family life to which a number of the 24 items are assigned. There are five possible answers to each item representing increasing severity of impairment (scores 0 to 4). The total scores ranged from 0 to 96 (best to worst QoL). In order to obtain scores of the individual subscales, the total score of each subscale (sum of the individual item scores) was transformed linearly to a 0 to 100 scale (best to worst QoL).\n\nThe mean changes in the CDQ-24 total score between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"16.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":"24.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"19.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.5","spread":"27.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"19.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"17.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.8","spread":"14.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"22.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":"18.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":"25.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"17.8"}]}]}]},{"type":"SECONDARY","title":"Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)","description":"The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).\n\nThe mean changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Categorical Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)","description":"The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).\n\nThe following categorical changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented: Improvement, No change and Deterioration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Without Pain and/or With a Reduction in Pain Based on a Global Assessment of Pain by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12)","description":"Global pain was assessed at Visit 2 (Week 4) and Visit 3 (Week 12); investigators and patients assessed change in global pain according to the following response categories:\n\n1. = no pain (anymore)\n2. = less pain\n3. = no change\n4. = more pain\n\nThe numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Assessment of Efficacy by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12)","description":"At Visit 2 (Week 4) and Visit 3 (Week 12) investigators and patients assessed global efficacy of injection of 500 U Dysport® according to the following response categories:\n\n1. = very good\n2. = good\n3. = moderate\n4. = insufficient\n\nThe numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":515},"commonTop":["Muscular weakness","Dysphagia","Neck pain","Nasopharyngitis","Headache"]}}}